[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Anil posts on X about $tmdx, $prok, role for, fed the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Social category influence finance XXXX%
Social topic influence $tmdx 17.65%, $prok 2.94%, role for 2.94%, fed 2.94%, accumulation 2.94%, avg 2.94%, flu 2.94%, $cdtx 2.94%, $2350next 2.94%, acquisition XXXX%
Top accounts mentioned or mentioned by @jonahlupton @s86coffeedev @avkeepitsimple @amrew84 @martychargin @aminekorchimd @contarloman8542 @hospitalmd1 @jinacapital @jeffgabel @biopharmiq @jb_equities @wklymarkets
Top assets mentioned TransMedics Group, Inc. Common Stock (TMDX)
Top posts by engagements in the last XX hours
"$PROK did a 12x in X days after Phase X data showed its kidney cell therapy reversed CKD decline by XX% in diabetics 🚀 327M shares traded 🚨 XX halts in a day 👀 Citi raised PT to $9" @AlphaBetaAnil on X 2025-07-10 23:27:50 UTC 8840 followers, 1185 engagements
"Well said. The case for an independent Fed is strong but do you think theres ever a role for more democratic oversight especially when monetary decisions have such profound effects on inequality and employment Curious where the balance should be between autonomy and accountability" @AlphaBetaAnil on X 2025-07-22 20:09:38 UTC 8839 followers, 1013 engagements
"$CDTX +137% gap on Ph2b flu data (76% efficacy) Volume: 19M (20x avg) 🚀 breakout confirmed X weeks of tight high-volume accumulation 📈 1-week low-volume pullback no distribution Classic institutional footprint 🧠This setups got serious legs" @AlphaBetaAnil on X 2025-07-23 00:22:26 UTC 8839 followers, XXX engagements
"$NKTR is up 300%+ since June on: ✅ Strong Phase 2b eczema data (46% EASI-75) ✅ Price targets hiked to $100$120 ✅ $115M offering boosts runway to 2026 ✅ Acquisition rumors swirling Now flagging near $23.50next leg higher or fade incoming" @AlphaBetaAnil on X 2025-07-18 14:30:26 UTC 8839 followers, 1755 engagements
"$TMDX is scaling exponentially: Supported 3700 transplants in 2024= tripling its 2022 volume projected 4600-4700 in 2025 Operates XX planes (targeting XX by end-2025) versus XVIVOs X Raised fullyear 2025 revenue guidance to $565M$585M (+2832%) Analysts project XX% sales growth in 2025 Meanwhile $XVIVO is down nearly XX% post-Q2 earnings and the fundamentals spell out why: Thoracic revenue sank XX% YoY EBITDA margin halved Operating profit plunged XX% EPS collapsed 94%" @AlphaBetaAnil on X 2025-07-16 15:37:57 UTC 8835 followers, 4113 engagements
"Everyones hyped about AI in medicine. Few are talking about the tech thats actually saving lives today. $TMDX is extending transplant viability improving outcomes and scaling like UPS for organs. Just quietly changing the future of medicine. And along the way Weak hands keep getting shaken outwhile the chart keeps climbing" @AlphaBetaAnil on X 2025-07-12 13:14:20 UTC 8839 followers, 5082 engagements
"$TMDX was mentioned in todays NYT report on DCD ethicsbut not for wrongdoing. Their surgeons halted the procedure when the donor showed signs of life. If stricter rules emerge hospitals will lean even harder on the safest most reliable platform" @AlphaBetaAnil on X 2025-07-20 22:47:16 UTC 8840 followers, 4294 engagements
"As a practicing cardiologist I can say this confidently: theres no real alternative to what $TMDX delivers. When it comes to organ perfusion and transplantation logistics theyre in a league of their own. End of story. No non sense. No noise" @AlphaBetaAnil on X 2025-07-12 01:11:56 UTC 8839 followers, 40K engagements
"Any company trying to compete with $TMDX is at least XX years behindjust based on the sheer depth of their R&D. This isnt a business you can disrupt overnight. Its a monopoly business. Sooner or later market will realize that" @AlphaBetaAnil on X 2025-07-12 01:45:15 UTC 8839 followers, 12K engagements
"Every $TMDX bull learns this the hard way: This stock loves to shake out weak handsdid it last year too after a soft Q3 Then ended up doing +9.1% more in H2 vs H1. Fast forward to 2025 Q1: $143.5M Q2 (est): $166.5M H1: $310M (+46.8% YoY) Even a repeat of last years H2 pattern gets you to $648M revs. Thats still way above both guidance (30%) and consensus (31.8%). Let them panic. You just need to zoom out" @AlphaBetaAnil on X 2025-07-18 04:56:40 UTC 8835 followers, 1608 engagements